Market
What will be the primary barrier to Xpert MTB/RIF Ultra adoption by end of 2025?
2
Resolution / Starting Odds
Cost • 25%
Infrastructure • 25%
Regulatory approval • 25%
Lack of awareness • 25%
WHO reports, research publications, or global health forums
Story
WHO Prequalifies First TB Diagnostic Test: Xpert MTB/RIF Ultra, Addressing Over a Million Deaths Annually
Dec 6, 2024, 09:36 PM
The World Health Organization (WHO) has announced the prequalification of the Xpert MTB/RIF Ultra test, marking it as the first diagnostic test for tuberculosis (TB) to meet WHO standards. This development is part of ongoing efforts to combat TB, which is responsible for over a million deaths annually. The endorsement of this rapid molecular test is seen as a significant step towards improving the accuracy and speed of TB diagnosis, particularly for drug-resistant strains. WHO Director-General Dr. Tedros Adhanom Ghebreyesus emphasized the importance of early detection in addressing this global health crisis.
View original story
Similar markets
Regulatory approvals • 25%
Public awareness • 25%
Cost • 25%
Manufacturing capacity • 25%
Distribution • 25%
Cost • 25%
Adherence • 25%
Regulatory approval • 25%
Regulatory hurdles • 25%
Other • 25%
Funding issues • 25%
Logistical challenges • 25%
Lack of awareness • 25%
Other • 25%
Cost of medication • 25%
Side effects • 25%
Cost • 25%
Regulatory Approval • 25%
Adherence • 25%
Distribution • 25%
Informed Consent Challenges • 25%
Other • 25%
Ethical Concerns • 25%
Logistical Issues • 25%
High adoption (75%+ countries) • 25%
Moderate adoption (50-74% countries) • 25%
Low adoption (25-49% countries) • 25%
Minimal adoption (<25% countries) • 25%
Staff shortages • 25%
Other • 25%
Lack of resources • 25%
Logistical issues • 25%
Patient Demand • 25%
Cost Efficiency • 25%
Accuracy Improvement • 25%
Time Saving • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Access to Medication • 25%
Ineffective Policies • 25%
Lack of Funding • 25%
Stigma and Discrimination • 25%
Regulatory hurdles • 25%
Other • 25%
Funding issues • 25%
Supply chain constraints • 25%